Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Natera Inc
(NQ:
NTRA
)
85.28
-2.00 (-2.29%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 19, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
2,526,074
Open
87.01
Bid (Size)
85.28 (1)
Ask (Size)
85.37 (5)
Prev. Close
87.28
Today's Range
83.13 - 87.19
52wk Range
36.90 - 98.82
Shares Outstanding
120,757,877
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Natera Announces Publication of Largest Prospective dd-cfDNA Study in Kidney Transplantation
April 11, 2024
From
Natera, Inc.
Via
Business Wire
Natera Announces New Data From Two Studies Extending the Clinical Validation of Its Prospera™ Heart dd-cfDNA Test for Heart Transplant Recipients
April 08, 2024
From
Natera, Inc.
Via
Business Wire
Performance
YTD
+37.73%
+37.73%
1 Month
-8.20%
-8.20%
3 Month
+27.99%
+27.99%
6 Month
+109.22%
+109.22%
1 Year
+57.23%
+57.23%
More News
Read More
Cracking The Code: Understanding Analyst Reviews For Natera
April 05, 2024
Via
Benzinga
Looking Into Natera's Recent Short Interest
April 05, 2024
Via
Benzinga
Natera Inc. (NASDAQ: NTRA) Records 52-Week High Friday Morning
April 05, 2024
Via
Investor Brand Network
Recap: Natera Q4 Earnings
February 28, 2024
Via
Benzinga
Natera Announces Positive Surveillance Analysis from the Randomized Phase III IMvigor011 Trial in Muscle-Invasive Bladder Cancer
April 05, 2024
From
Natera, Inc.
Via
Business Wire
Natera and Alliance for Clinical Trials in Oncology Announce Activation of Alliance A032103 (MODERN): A Randomized, Phase II/III Adjuvant Trial in Urothelial Cancer
April 01, 2024
From
Natera, Inc.
Via
Business Wire
Natera Announces Phase III Randomized CIRCULATE Trial in France, Evaluating Signatera™ in Stage II Colorectal Cancer
March 18, 2024
From
Natera, Inc.
Via
Business Wire
Earnings Preview For Natera
February 27, 2024
Via
Benzinga
A Glimpse Into The Expert Outlook On Natera Through 9 Analysts
February 20, 2024
Via
Benzinga
New KDIGO Guideline Supports Genetic Testing for the Majority of CKD Patients to Establish Cause of Disease
March 14, 2024
From
Natera, Inc.
Via
Business Wire
Disney, Natera, Chubb And A Major Tech Stock On CNBC's 'Final Trades'
March 12, 2024
Via
Benzinga
Natera to Present New Data at the 2024 SGO Annual Meeting on Women’s Cancer, Following Recent Medicare Coverage Decisions in Ovarian and Breast Cancers
March 12, 2024
From
Natera, Inc.
Via
Business Wire
9 Health Care Stocks Whale Activity In Today's Session
March 08, 2024
Via
Benzinga
Natera Announces Commercial Coverage for Prospera™ Kidney and Prospera Heart™ from a Top BCBS Plan
March 07, 2024
From
Natera, Inc.
Via
Business Wire
Agilent Technologies Stock Getting Closer To Key Technical Benchmark
March 05, 2024
Via
Investor's Business Daily
Wall Street Takes A Breather As Inflation Stays Tamed, AMD Hits Record Highs, Apple Struggles: What's Driving Markets Thursday?
February 29, 2024
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
Natera to Participate in March Investor Conferences
February 29, 2024
From
Natera, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Wednesday's After-Market Session
February 28, 2024
Via
Benzinga
Natera Reports Fourth Quarter and Full Year 2023 Financial Results
February 28, 2024
From
Natera, Inc.
Via
Business Wire
Cathie Wood's Ark Invest Sheds $9.3M Worth Of Coinbase Shares Amid Bitcoin Rally — Robinhood Stock Also Sold
February 27, 2024
Via
Benzinga
Earnings Scheduled For February 28, 2024
February 28, 2024
Via
Benzinga
Natera Announces Next Phase of CareDx Patent Infringement Litigation Seeking Royalty For All Ongoing And Future AlloSure Tests
February 27, 2024
From
Natera, Inc.
Via
Business Wire
Medicare Extends Coverage of Natera’s Signatera™ MRD Test to Ovarian Cancer and Neoadjuvant Breast Cancer
February 26, 2024
From
Natera, Inc.
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.